[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635391":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":26,"responsibleParty":100,"collaborators":11,"id":102,"slug":103,"hasResults":104,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":104,"sex":109,"minAge":110,"maxAge":11,"enrollmentInfo":111,"targetDuration":11,"studyType":114,"phases":115,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":51,"whyStopped":11,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":131},{"fullName":5,"class":6},"Palvella Therapeutics, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Open label","EXPERIMENTAL",null,[13],"Drug: PTX-022",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","PTX-022","topical administration of PTX-022",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Emily Cook","CONTACT","267-738-6366","emily.cook@palvellatx.com",[27,49,68,83],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Unified Health","NOT_YET_RECRUITING","Sherman Oaks","California","91403","United States","US",{"type":36,"coordinates":37},"Point",[38,39],-118.44925,34.15112,{"lat":39,"lon":38},[42,46],{"name":43,"role":23,"phone":44,"phoneExt":11,"email":45},"Jamie Goodnight","(833) 525-CURA (2872)","jgoodnight@curaclinicalresearch.com",{"name":47,"role":48,"phone":11,"phoneExt":11,"email":11},"Michael Lin, MD","PRINCIPAL_INVESTIGATOR",{"facility":50,"status":51,"city":52,"state":53,"zip":54,"country":33,"countryCode":34,"cosmosGeoPoint":55,"geoPoint":59,"contacts":60},"Cleaver Medical Group","RECRUITING","Dawsonville","Georgia","30534",{"type":36,"coordinates":56},[57,58],-84.11908,34.42121,{"lat":58,"lon":57},[61,66],{"name":62,"role":23,"phone":63,"phoneExt":64,"email":65},"Dana Anderson","770.800.3455","1014","danderson@cleavermedicalgroup.com",{"name":67,"role":48,"phone":11,"phoneExt":11,"email":11},"Nathan Cleaver, MD",{"facility":69,"status":29,"city":70,"state":71,"zip":72,"country":33,"countryCode":34,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"Vividia Dermatology","Las Vegas","Nevada","89148",{"type":36,"coordinates":74},[75,76],-115.13722,36.17497,{"lat":76,"lon":75},[79,82],{"name":80,"role":23,"phone":11,"phoneExt":11,"email":81},"Graham Lichtman, MD","graham.litchman@gmail.com",{"name":80,"role":48,"phone":11,"phoneExt":11,"email":11},{"facility":84,"status":51,"city":85,"state":86,"zip":87,"country":33,"countryCode":34,"cosmosGeoPoint":88,"geoPoint":92,"contacts":93},"Epiphany Dermatology","Southlake","Texas","76092",{"type":36,"coordinates":89},[90,91],-97.13418,32.94124,{"lat":91,"lon":90},[94,98],{"name":95,"role":23,"phone":96,"phoneExt":11,"email":97},"Moraima Avalos","(214) 884 - 7558","chintan@stryderesearch.com",{"name":99,"role":48,"phone":11,"phoneExt":11,"email":11},"Todd Plott, MD",{"type":101,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100635391","phase-2-a-phase-2-baseline-controlled-study-evaluating-the-safety-and-efficacy-of-ptx-022-sirolimus-topical-gel-39-in-the-treatment-of-angiokeratomas-lotu-100635391",false,"NCT07552077","A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)","LOTU","Inclusion Criteria:\n\n* Participants must be 6 years or older\n* Diagnosed with angiokeratoma\n* Able and willing to comply with all protocol-related activities\n* Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* Any significant concurrent condition that could adversely affect participation\n* Any history of allergy or hypersensitivity to sirolimus, or sirolimus-like medications or to PTX-022\n* Patients deemed by the investigator as unwilling or unable to remain compliant with all tests and procedures, including adherence to study drug administration and other protocol-required activities","ALL","6 Years",{"count":112,"type":113},15,"ESTIMATED","INTERVENTIONAL",[116],"PHASE2","The purpose of this study is to evaluate the safety and effectiveness of the experimental drug PTX-022 in the treatment of angiokeratomas",[119],"Angiokeratomas",[121],"angiokeratoma","2026-04-20",{"date":124,"type":125},"2026-04-27","ACTUAL",{"date":127,"type":113},"2026-04",{"date":129,"type":113},"2027-09",{"name":5,"class":6},4]